Lornoxicam | CAS#70374-39-9

MedKoo Cat#: 318165 | Name: Lornoxicam

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lornoxicam is a new nonsteroidal anti-inflammatory drug of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug.

Chemical Structure

Lornoxicam

CAS#70374-39-9

Theoretical Analysis

MedKoo Cat#: 318165

Name: Lornoxicam

CAS#: 70374-39-9

Chemical Formula: C13H10ClN3O4S2

Exact Mass: 370.9801

Molecular Weight: 371.81

Elemental Analysis: C, 41.99; H, 2.71; Cl, 9.54; N, 11.30; O, 17.21; S, 17.25

Price and Availability

Size	Price	Availability	Quantity
1g	USD 350.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Lornoxicam; Chlortenoxicam; Xefo; Lornoxicamum; Xefocam; xefocam; Ro 13-9297; Ro13-9297; TS 110; TS-110; TS110

IUPAC/Chemical Name

6-Chloro-4-hydroxy-2-methyl-N-(2-pyridyl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-Dioxide

InChi Key

WLHQHAUOOXYABV-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)

SMILES Code

CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Lornoxicam (Chlortenoxicam), a COX-1 and COX-2 inhibitor, is a new nonsteroidal anti-inflammatory drug (NSAID).

In vitro activity:

In intact human cells, lornoxicam showed a balanced inhibition of COX-1/-2 exhibiting the lowest IC50 (0.005 microM/0.008 microM) of the large panel of NSAIDs tested. NO formation was dose-dependently inhibited by lornoxicam (IC50 of 65 microM) whereas piroxicam, diclofenac, ibuprofen, ketorolac and naproxen inhibited the NO formation markedly less. Reference: Inflamm Res. 1999 Jul;48(7):369-79. https://pubmed.ncbi.nlm.nih.gov/10450786/

In vivo activity:

A corneal latent herpes simplex virus-1 (HSV-1) infected mouse model was established. Six weeks later, Ultraviolet B (UVB) irradiation induced the recurrence. Lornoxicam treatment significantly decreased the incidence of recurrent HSK, attenuated the corneal opacity scores, and also effectively suppressed both NF-kappaB activation and TNF-alpha expression in biological analysis. Reference: Mol Vis. 2009 Jun 14;15:1252-9. https://pubmed.ncbi.nlm.nih.gov/19547717/

	Solvent	mg/mL	mM
Solubility
	DMSO	2.9	7.80

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 371.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Hussen J, Kandeel M, Shawaf T, Al-Mubarak AIA, Al-Humam NA, Almathen F. Immunomodulatory Effects of the Cyclooxygenase Inhibitor Lornoxicam on Phenotype and Function of Camel Blood Leukocytes. Animals (Basel). 2021 Jul 6;11(7):2023. doi: 10.3390/ani11072023. PMID: 34359151; PMCID: PMC8300418. 2. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. doi: 10.1007/s000110050474. PMID: 10450786. 3. Yin J, Huang Z, Xia Y, Ma F, Zhang LJ, Ma HH, Li Wang L. Lornoxicam suppresses recurrent herpetic stromal keratitis through down-regulation of nuclear factor-kappaB: an experimental study in mice. Mol Vis. 2009 Jun 14;15:1252-9. PMID: 19547717; PMCID: PMC2697669.

In vitro protocol:

In vivo protocol:

1. Yin J, Huang Z, Xia Y, Ma F, Zhang LJ, Ma HH, Li Wang L. Lornoxicam suppresses recurrent herpetic stromal keratitis through down-regulation of nuclear factor-kappaB: an experimental study in mice. Mol Vis. 2009 Jun 14;15:1252-9. PMID: 19547717; PMCID: PMC2697669.

1: Larif S, Slim R, Fathallah N, Ghariani N, Hmouda H, Salem CB. Lornoxicam-induced acute generalized exanthematous pustulosis. Int J Dermatol. 2016 Mar 11. doi: 10.1111/ijd.13252. [Epub ahead of print] PubMed PMID: 26971725. 2: Çelik H, Abdullayev R, Akçaboy EY, Baydar M, Göğüş N. [Comparison of tramadol and lornoxicam in intravenous regional anesthesia: a randomized controlled trial]. Rev Bras Anestesiol. 2016 Jan-Feb;66(1):44-9. doi: 10.1016/j.bjan.2015.11.003. Epub 2015 Nov 29. Portuguese. PubMed PMID: 26647089. 3: Çelik H, Abdullayev R, Akçaboy EY, Baydar M, Göğüş N. Comparison of tramadol and lornoxicam in intravenous regional anesthesia: a randomized controlled trial. Braz J Anesthesiol. 2016 Jan-Feb;66(1):44-9. doi: 10.1016/j.bjane.2014.07.013. Epub 2015 Mar 29. PubMed PMID: 26768929. 4: Salama AH, Shamma RN. Tri/tetra-block co-polymeric nanocarriers as a potential ocular delivery system of lornoxicam: in-vitro characterization, and in-vivo estimation of corneal permeation. Int J Pharm. 2015 Aug 15;492(1-2):28-39. doi: 10.1016/j.ijpharm.2015.07.010. Epub 2015 Jul 4. PubMed PMID: 26151106. 5: Gorsky VA, Agapov MA, Khoreva MV, Leonenko IV. The effect of lornoxicam on TLR2 and TLR4 messenger RNA expression and tumor necrosis factor-α, interleukin-6, and interleukin-8 secretion in patients with systemic complications of acute pancreatitis. Pancreas. 2015 Jul;44(5):824-30. doi: 10.1097/MPA.0000000000000344. PubMed PMID: 25872171. 6: Patel JC, Patel PB, Acharya H, Nakum K, Tripathi CB. Efficacy and safety of lornoxicam vs ibuprofen in primary dysmenorrhea: a randomized, double-blind, double dummy, active-controlled, cross over study. Eur J Obstet Gynecol Reprod Biol. 2015 May;188:118-23. doi: 10.1016/j.ejogrb.2015.03.005. Epub 2015 Mar 9. PubMed PMID: 25808572. 7: Abdel-Ghaffar HS, Abdel-Azeem HG, Roushdy MM. Safety and efficacy of pre-incisional peritonsillar lornoxicam in paediatric post-tonsillectomy pain: a prospective double-blind, placebo-controlled, split-body clinical study. Clin Otolaryngol. 2015 Jun;40(3):219-26. doi: 10.1111/coa.12351. PubMed PMID: 25404551. 8: Anumolu PD, Sunitha G, Bindu SH, Satheshbabu PR, Subrahmanyam CV. Development and Validation of Discriminating and Biorelevant Dissolution Test for Lornoxicam Tablets. Indian J Pharm Sci. 2015 May-Jun;77(3):312-20. PubMed PMID: 26180277; PubMed Central PMCID: PMC4502146. 9: Kotsovolis G, Karakoulas K, Grosomanidis V, Tziris N. Comparison between the combination of gabapentin, ketamine, lornoxicam, and local ropivacaine and each of these drugs alone for pain after laparoscopic cholecystectomy: a randomized trial. Pain Pract. 2015 Apr;15(4):355-63. doi: 10.1111/papr.12183. Epub 2014 Feb 27. PubMed PMID: 24571062. 10: Gönüllü Ü, Üner M, Yener G, Karaman EF, Aydoğmuş Z. Formulation and characterization of solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsion of lornoxicam for transdermal delivery. Acta Pharm. 2015 Mar;65(1):1-13. doi: 10.1515/acph-2015-0009. PubMed PMID: 25781700. 11: Alharbi MB. Lornoxicam Side Effects May Lead to Surgical Mismanagement, in Case of Postoperative Intra-Abdominal Collection: A Case Report and Literature Review. Case Rep Surg. 2015;2015:545807. doi: 10.1155/2015/545807. Epub 2015 Aug 31. PubMed PMID: 26417471; PubMed Central PMCID: PMC4568387. 12: Kilbaş Z, Menteş MÖ, Harlak A, Yiğit T, Balkan SM, Coşar A, Öztürk E, Kozak O, Tufan CT. Efficacy of wound infiltration with lornoxicam for postoperative analgesia following thyroidectomy: a prospective, randomized, double-blind study. Turk J Med Sci. 2015;45(3):700-5. PubMed PMID: 26281342. 13: Hadi MA, Rao NG, Rao AS. Formulation and evaluation of mini-tablets-filled-pulsincap delivery of lornoxicam in the chronotherapeutic treatment of rheumatoid arthritis. Pak J Pharm Sci. 2015 Jan;28(1):185-93. PubMed PMID: 25553695. 14: Abdelbary GA, Aburahma MH. Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain. J Liposome Res. 2015;25(2):107-21. doi: 10.3109/08982104.2014.941861. Epub 2014 Jul 24. PubMed PMID: 25058447. 15: Li F, Song S, Guo Y, Zhao Q, Zhang X, Pan W, Yang X. Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam. Drug Deliv. 2015;22(4):487-98. doi: 10.3109/10717544.2014.885615. Epub 2014 Feb 13. PubMed PMID: 24524289. 16: Sun HL, Dong YC, Wang CQ, Qian YN, Wang ZY. Effects of postoperative analgesia with the combination of tramadol and lornoxicam on serum inflammatory cytokines in patients with gastric cancer. Int J Clin Pharmacol Ther. 2014 Dec;52(12):1023-9. doi: 10.5414/CP202190. PubMed PMID: 25295719. 17: Gorskii VA, Agapov MA, Khoreva MV, Petrov VA, Kravchenko AY, Battaev AI. Effect of lornoxicam therapy on expression of TLR2 and TLR4 mRNA during systemic complications of acute pancreatitis. Bull Exp Biol Med. 2014 Nov;158(1):13-5. doi: 10.1007/s10517-014-2680-0. Epub 2014 Nov 19. PubMed PMID: 25403387. 18: Işik B, Yaman S, Aktuna S, Turan A. Analgesic efficacy of prophylactic gabapentin and lornoxicam in preventing postendodontic pain. Pain Med. 2014 Dec;15(12):2150-5. doi: 10.1111/pme.12536. Epub 2014 Aug 19. PubMed PMID: 25138784. 19: Nijhawan M, Santhosh A, Babu PR, Subrahmanyam CV. Solid state manipulation of lornoxicam for cocrystals--physicochemical characterization. Drug Dev Ind Pharm. 2014 Sep;40(9):1163-72. doi: 10.3109/03639045.2013.804834. Epub 2013 Jul 5. PubMed PMID: 23829186. 20: Tawfeek HM, Saleem IY, Roberts M. Dissolution enhancement and formulation of rapid-release lornoxicam mini-tablets. J Pharm Sci. 2014 Aug;103(8):2470-83. doi: 10.1002/jps.24073. Epub 2014 Jul 3. PubMed PMID: 24995853.